Clinical trial
A Prospective, Randomized, Multi-center Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination With 1-month Dual Antiplatelet Therapy (DAPT)
NCT04137510 is registered in ClinicalTrials.gov with Biotronik AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Multi-center Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination With 1-month Dual Antiplatelet Therapy (DAPT)
- Lead sponsor
- Biotronik AG
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 24, 2020
- Completion date
- September 20, 2022
- Enrollment
- 1,948 (actual)
- Sites
- 53
Conditions
As the registry lists them; a condition with its own page is linked.